The Biotech company Acesion Pharma has taken up a Covid-19 emergency loan worth DKK 20m from the Danish Growth Fund to keep the engines running. An important phase II study has been postponed by at least six months, according to the firm's executive chairman.
BY ALBERT RØNNING-ANDERSSON, TRANSLATED BY NIELSINE NIELSEN
Log in to read our articles
Welcome to MedWatch. A part of our content is exclusive and reserved for our users.